-
Ciloa SAS
Created in 2011
-
-
Trend leader (A+)
Existing signals make this entity one of the most dynamic startups -
Social networks
1,950 -
Activities
-
Technologies
-
Entity types
-
Location
356 Rue Maurice Béjart, 34080 Montpellier, France
Montpellier
France
-
Employees
Scale: 11-50
Estimated: 14
-
Engaged catalyst
6
0 0 -
Added in Motherbase
3 years, 2 months ago
-
Value proposition
Harnessing natural messengers for innovative therapeutics
Ciloa is a pioneer in the bioengineering of extracellular vesicles to develop new generations of therapeutics and preventive solutions to improve patients' lives.
Ciloa bioengineers sEV proteins, to turn them into natural messengers with huge medical potential. Our bioengineered sEVs can be used as therapeutic solutions in a number of medical fields, including oncology, metabolic diseases, rare diseases and age-related illnesses. Mastering sEV engineering, we have produced sEVs containing a stable, highly multimerised and functional adiponectin (APN), a hormone well known as our “Guardian Angel” for its insulin-sensitizing, anti-inflammatory and anti-oxidative stress properties. Ciloa’s platform, EVENGI, has generated over a hundred sEVs containing various proteins of medical interest. Thanks to our 20 years’ experience in the field of EVs, we have developed a robust sEV production, purification and qualification process that can be scaled up under industrial conditions. This EV production platform has enabled us to produce dozens of bioengineered sEVs that are stable in the refrigerator for years as ready-to-use, affordable medicines.
Screening ligand binding to membrane receptors, Development of native transmembrane proteins, Development of therapeutic antibodies, Development of vaccines, Development of therapeutic vectors, Pioneer of exosome based therapies and vaccines, Metabolic diseases therapies, Adiponectin on sEVs, and Small Extracellular vesicles therapies and vaccines -
Original language
Harnessing natural messengers for innovative therapeutics
Ciloa is a pioneer in the bioengineering of extracellular vesicles to develop new generations of therapeutics and preventive solutions to improve patients' lives.
Ciloa bioengineers sEV proteins, to turn them into natural messengers with huge medical potential. Our bioengineered sEVs can be used as therapeutic solutions in a number of medical fields, including oncology, metabolic diseases, rare diseases and age-related illnesses. Mastering sEV engineering, we have produced sEVs containing a stable, highly multimerised and functional adiponectin (APN), a hormone well known as our “Guardian Angel” for its insulin-sensitizing, anti-inflammatory and anti-oxidative stress properties. Ciloa’s platform, EVENGI, has generated over a hundred sEVs containing various proteins of medical interest. Thanks to our 20 years’ experience in the field of EVs, we have developed a robust sEV production, purification and qualification process that can be scaled up under industrial conditions. This EV production platform has enabled us to produce dozens of bioengineered sEVs that are stable in the refrigerator for years as ready-to-use, affordable medicines.
-
ciloa.bio
Harnessing natural messengers for innovative therapeutics Ciloa is a pioneer in the bioengineering of extracellular vesicles to develop new generations of thera
https://ciloa.bio/
| Catalyst | Type | Tweets | Articles | |
|---|---|---|---|---|
Agence Régionale de Santé Occitanie (ARS)
Government Administration (Auto) |
Agence Régionale de Santé Occitanie (ARS)
Government Administration (Auto) |
Other
11 Dec 2025 |
|
|
Gouvernement
Government Administration (Auto) |
Gouvernement
Government Administration (Auto) |
Other
11 Dec 2025 |
|
|
SATT AxLR
Research Services (Auto) |
SATT AxLR
Research Services (Auto) |
Other
7 Mar 2025 |
|
|
Créalia Occitanie
Civic and Social Organizations (Auto) |
Créalia Occitanie
Civic and Social Organizations (Auto) |
Other
15 Mar 2024 |
|
|
French Tech Méditerranée
French Tech, Technology, Information and Internet (Auto) |
French Tech Méditerranée
French Tech, Technology, Information and Internet (Auto) |
Other
14 Mar 2024 |
|
|
Eurobiomed
Public business cluster, Biotechnology, French Cluster, Non-profit Organizations (Auto) |
Eurobiomed
Public business cluster, Biotechnology, French Cluster, Non-profit Organizations (Auto) |
Other
11 Dec 2025 |
|
|